Skip to content

Investors Overview

Esperion is a late-stage pharmaceutical company passionately committed to developing and commercializing complementary, non-statin, once-daily, oral therapies to lower elevated  low density lipoprotein (LDL) cholesterol for patients with hypercholesterolemia not adequately treated with current lipid-modifying therapies.  Bempedoic acid, a convenient, complementary, cost-effective, once-daily, oral inhibitor of ATP Citrate Lyase (ACLi) brings a targeted mechanism of action to address patients unmet medical needs in a way that is "patient-friendly, physician-friendly, and payer-friendly”.

Esperion has been a publicly traded company since 2013 and is listed on the NASDAQ Global Select Market under the symbol ESPR.



Esperion Therapeutics (NASDAQ: ESPR) 10:12 AM ET on Oct 18, 2017
Last Price 50.80 Change -1.41(-2.698%) open 52.52 Day High 52.56 52-Week High 57.40
Volume 49,119 Previous Close 52.21 Day Low 50.71 52-Week Low 9.40

Press Releases

Load More